[1S-(1β,4β,7aβ)]-[1R-(3aα)]-octahydro-1-acetyl-4-[(tert-butyldimethylsilyl)oxy]-7a-methyl-1H-indene | 140659-43-4

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: [1S-(1β,4β,7aβ)]-[1R-(3aα)]-octahydro-1-acetyl-4-[(tert-butyldimethylsilyl)oxy]-7a-methyl-1H-indene
• 英文别名: des-A,B-8β-[(tert-butyldimethylsilyl)oxy]-pregnan-20-one；(1S-(1α,3aβ,4α,7aα))-Octahydro-1-acetyl-4-[(tert-butyldimethylsilyl)oxy]-7a-methyl-1H-indene；Ethanone, 1-[(1S,3aR,4S,7aS)-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]-；1-[(1S,3aR,4S,7aS)-4-[tert-butyl(dimethyl)silyl]oxy-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-1-yl]ethanone
• CAS: 140659-43-4
• 化学式: C₁₈H₃₄O₂Si
• 分子量: 310.552
• InChiKey: NHWSULVSYVPIIS-MUQADHOPSA-N

物化性质

• 沸点：
  346.4±25.0 °C(Predicted)
• 密度：
  0.94±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.18
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [1S-(1β,4β,7aβ)]-[1R-(3aα)]-octahydro-1-acetyl-4-[(tert-butyldimethylsilyl)oxy]-7a-methyl-1H-indene 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 氢化钾 作用下， 以 乙醇 、 异丙醇 、 苯 为溶剂， 反应 12.0h， 生成 ethyl 3-[(1S)-1-[(1S,3aR,4S,7aR)-4-[tert-butyl(dimethyl)silyl]oxy-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-1-yl]ethoxy]propanoate
  参考文献：
  名称：

  A new approach to the synthesis of the 25-hydroxy-22-oxa-vitamin D3 side chain

  摘要：

  An efficient new method is described for the construction of the 25-hydroxy-22-oxavitamin D-3 side-chain, which is present in several analogues of calcitriol with antitumour activity. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)01056-3
• 作为产物：
  描述：

  (S)-2-((3R,3aR,7S,7aR)-octahydro-7-hydroxy-3a-methyl-1H-inden-3-yl)propyl 4-methylbenzenesulfonate 在 咪唑 、 potassium tert-butylate 、 氧气 、 碳酸氢钠 、 二甲基亚砜 作用下， 以 叔丁醇 为溶剂， 生成 [1S-(1β,4β,7aβ)]-[1R-(3aα)]-octahydro-1-acetyl-4-[(tert-butyldimethylsilyl)oxy]-7a-methyl-1H-indene
  参考文献：
  名称：

  A new approach to the synthesis of the 25-hydroxy-22-oxa-vitamin D3 side chain

  摘要：

  An efficient new method is described for the construction of the 25-hydroxy-22-oxavitamin D-3 side-chain, which is present in several analogues of calcitriol with antitumour activity. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)01056-3

文献信息

• 2-Methylene-(20E)-20(22)-Dehydro-19-Nor-Vitamin D Analogs
  申请人：DeLuca Hector F.

  公开号：US20100009940A1

  公开（公告）日：2010-01-14

  This invention discloses 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(20E)-20(22)-dehydro-19-nor-1α,25-dihydroxyvitamin D 3 , and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and similar in vivo intestinal calcium transport activity compared to the native hormone 1α,25-dihydroxyvitamin D 3 , and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  本发明公开了2-亚甲基-(20E)-20(22)-去氢-19-去氢维生素D类似物，特别是2-亚甲基-(20E)-20(22)-去氢-19-去氢-1α,25-二羟基维生素D3，并提供了其药用用途。该化合物表现出相对较高的转录活性，以及在阻止未分化细胞增殖和诱导它们分化为单核细胞方面表现出显著活性，从而证明其作为抗癌剂以及用于治疗银屑病等皮肤疾病以及皮肤问题，如皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足的用途。该化合物在体内对骨钙动员的活性较低，并且与天然激素1α,25-二羟基维生素D3相比，在体内肠钙转运活性类似，因此可用于治疗人类的自身免疫性疾病或炎症性疾病以及肾性骨病。该化合物还可用于治疗或预防肥胖。
• 2-Methylene-20(21)-Dehydro-19-Nor-Vitamin D Analogs
  申请人：DeLuca Hector F.

  公开号：US20100009941A1

  公开（公告）日：2010-01-14

  This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D 3 , and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and similar in vivo intestinal calcium transport activity compared to the native hormone 1αa,25-dihydroxyvitamin D 3 , and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  本发明揭示了2-亚甲基-20(21)-去氢-19-去氢维生素D类似物，具体包括2-亚甲基-20(21)-去氢-19-去氢-1α,25-二羟基维生素D3，以及其药用用途。该化合物表现出相对较高的转录活性，以及在阻止未分化细胞增殖和诱导它们分化为单核细胞方面的显著活性，从而表明其用作抗癌剂以及用于治疗银屑病等皮肤疾病以及皮肤状况，如皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足。该化合物在体内对骨钙动员的活性较低，并且与天然激素1α,25-二羟基维生素D3相比，在体内肠钙转运活性类似，因此可用于治疗人类的自身免疫性疾病或炎症性疾病以及肾性骨病。该化合物还可用于肥胖的治疗或预防。
• Synthesis of Novel Analogues of 1α,25-Dihydroxyvitamin D₃ with Side Chains at C-18
  作者：Edelmiro Momán、Daniel Nicoletti、Antonio Mouriño

  DOI：10.1021/jo0498664

  日期：2004.7.1

  Novel analogues of the hormone 1α,25-(OH)2-D3 with side chains attached to C-18 were synthesized by a versatile route in which key steps were the remote radical-induced functionalization of the 18-methyl by the C-8β-hydroxyl group and the introduction of the side chains by Wittig reactions on a C-18-aldehyde. The triene system of the novel analogues was constructed by the convergent Lythgoe−Hoffmann

  通过一条通用途径合成了带有连接到C-18的侧链的1α，25-（OH）2 -D 3激素的新类似物，其中的关键步骤是C-对18-甲基的远程自由基诱导的官能化8β-羟基和通过在C-18-醛上的Wittig反应引入侧链。新的类似物的三烯系统是通过收敛的Lythgoe-Hoffmann la Roche方法构建的，该方法涉及氧化膦（环A片段）与酮（上部片段）的反应。
• Synthesis and structure–activity relationships of 16-ene-22-thia-1α,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs having side chains of different sizes
  作者：Hajime Takaku、Yukiko Miyamoto、Shiori Asami、Mika Shimazaki、Sachiko Yamada、Keiko Yamamoto、Nobuyuki Udagawa、Hector F. DeLuca、Masato Shimizu

  DOI：10.1016/j.bmc.2007.11.013

  日期：2008.2.15

  We have synthesized eight novel 16-ene-22-thia-26,27-dimethyl-19-norvitamin D3 analogs 1-5 bearing side chains of different sizes, in combination with 20S- and 20R-isomers. The target compounds were prepared by Wittig-Horner reaction of A-ring phosphine oxide with 16-ene-22-thia-25-hydroxy Grundmann's ketones having different sized side chains, which were derived from the S-phenyloxycarbonyl derivative

  我们已经合成了八个带有不同大小侧链的16-ene-22-thia-26,27-二甲基-19-norvitamin D3类似物1-5，与20S和20R异构体结合在一起。通过A-环氧化膦与具有不同侧链尺寸的16-烯-22-噻-25-羟基格伦德曼酮的Wittig-Horner反应制备目标化合物，所述酮衍生自作为主要中间体的S-苯氧羰基衍生物13。研究了合成的22-thia-19-norvitamin D类似物1-5对维生素D受体（VDR）的结合亲和力，VDR介导的转录活性和破骨细胞诱导活性。就体外测试的生物学活性而言，（20S）-22-硫杂-19,24-地诺维生素D类似物1a与天然激素1α，25-二羟基维生素D3（1α，25-（OH）2D3）具有相同的活性。类似物2a和3a在与VDR的结合中表现出与1alpha，25-（OH）2D3几乎相同的效能，在转录活性方面比1alpha，25-（OH）2D
• A facile stereoselective route to a C/D-ring synthon for 20-epi-22-oxavitamin D3 analogues
  作者：Susumi Hatakeyama、Tatsuhiko Ikeda、Hiroshi Irie、Chino Izumi、Hisato Mori、Kohsei Uenoyama、Hidetoshi Yamada、Mugio Nishizawa

  DOI：10.1039/c39950001959

  日期：——

  An efficient method for the preparation of a C/D-ring synthon for 20-epi-22-oxavitamin D3 analogues is developed based on Me3SiOSO2CF3 catalysed reductive etherification of a ketone with an alkoxytrimethylsilane in the presence of triethylsilane.

  在三乙基硅烷存在下，基于Me 3 SiOSO 2 CF 3催化的酮与烷氧基三甲基硅烷的还原性醚化作用，开发了一种有效的方法来制备20-表-22-恶维他命D 3类似物的C / D环合成子。